SOUTH SAN FRANCISCO, Calif., Sept. 7, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, will present data suggesting improved one-year survival with ZYBRESTAT compared to historical survival rates in patients with anaplastic thyroid cancer (ATC) at the upcoming 35th Meeting of the European Thyroid Association, in Krakow, Poland on September 14, 2011. OXiGENE will release a summary of results immediately after they are presented.
ZYBRESTAT Presentation Details:
Oral Presentation Title: FOSBRETABULIN TROMETHAMINE (CA4P), A TUBULIN-BINDING VASCULAR DISRUPTING AGENT (VDA), IS ASSOCIATED WITH IMPROVED 1-YEAR SURVIVAL IN ANAPLASTIC THYROID CANCER (ATC) PATIENTS TREATED IN 5 INDEPENDENT PROSPECTIVE STUDIES COMPARED TO A LARGE SINGLE INSTITUTION HISTORICAL SERIES
Presenter: Rossella Elisei, M.D.
Session Title: Thyroid Cancer Clinical
Date: Wednesday, September 14, 2011
Time of session: 8:00-10:00 a.m. Central European Time
Location: Main Hall (Aula Duza)
About ZYBRESTAT
ZYBRESTAT is being evaluated in a Phase 2 study of patients with non-squamous non-small cell lung cancer and other clinical trials, including a recently completed Phase 2 study of ZYBRESTAT plus chemotherapy in patients with anaplastic thyroid cancer (ATC). OXiGENE believes that ZYBRESTAT is poised to become an important product in a novel class of small-molecule drug candidates called vascular disrupting agents. Through interaction with vascular endothelial cell cytoskeletal proteins, ZYBRESTAT selectively targets and collapses tumor vasculature, thereby depriving the tumor of oxygen and causing death of tumor cells. In clinical trials in solid tumors, ZYBRESTAT has demonstrated potent and selective activity against tumor vasculature, as well as clinical activity against anaplastic thyroid cancer, ovarian cancer and various other solid tumors.
About OXiGENE, Inc.
OXiGENE is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat cancer and eye diseases. The Company's major focus is the clinical advancement of drug candidates that selectively disrupt abnormal blood vessels associated with solid tumor progression and visual impairment. OXiGENE is dedicated to leveraging its intellectual property position and therapeutic development expertise to bring life saving and enhancing medicines to patients.
The OXiGENE, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4969
Safe Harbor Statement
This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Any or all of the forward-looking statements in this press release, which include projected study outcomes, emerging oncology treatments and the expected conclusion of ongoing or initiation of new clinical studies may turn out to be wrong. Forward-looking statements can be affected by inaccurate assumptions OXiGENE might make or by known or unknown risks and uncertainties, including, but not limited to, the outcome of clinical studies and the availability of additional financing to continue development of ZYBRESTAT. Additional information concerning factors that could cause actual results to materially differ from those in the forward-looking statements is contained in OXiGENE's reports to the Securities and Exchange Commission, including OXiGENE's reports on Form 10-K, 10-Q and 8-K. However, OXiGENE undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise. Please refer to our Annual Report on Form 10-K for the fiscal year ended December 31, 2010.